Table 1.
Baseline characteristics of the study groups
| Characteristics | Standard care group (n = 791) |
R6M group (n = 1166) |
p-value for difference between the group | |
|---|---|---|---|---|
| Age, mean (SD) years | 40.1 (10.9) | 41.8 (10.8) | 0.0007 | |
| Gender, n (%) | ||||
| Male | 229 (28.9) | 383 (32.8) | ||
| Female | 562 (71.0) | 783 (67.2) | ||
| Total | 791 (100) | 1166 (100) | 0.068 | |
| Current CD4 count, mean (SD) cells/μl | 497 (261) | 494 (243) | 0.769 | |
| Baseline Viral Load for eligibility in copies/μl, n (%) | ||||
| < 250 | 741 (93.7) | 1145 (98.2) | ||
| 250–1000 | 50 (6.3) | 21 (1.8) | ||
| Total | 791 (100) | 1166 (100) | < 0.001 | |
| TB status at any follow-up visit, n (%) | ||||
| Negative/Unknown | 778 (98.4) | 1150 (98.6) | ||
| Positive | 13 (1.6) | 16 (1.4) | ||
| Total | 791 (100) | 1166 (100) | 0.626 | |
| Duration on ART in months, n (%) | ||||
| < 60 | 419 (53.9) | 557 (47.8) | ||
| ≥ 60 | 358 (46.1) | 609 (52.2) | ||
| Total | 777 (100) | 1166 (100) | 0.008 | |
| TDF-3TC-EFV regimen, n (%) | ||||
| No | 366 (46.3) | 202 (17.3) | ||
| Yes | 425 (53.7) | 963 (82.7) | ||
| Total | 791 (100) | 1165 (100) | <0.001 | |
| Outcome, n (%) | ||||
| In care | 707 (89.4) | 1109 (95.1) | ||
| Lost to Follow-up | 74 (9.4) | 45 (3.9) | ||
| Dead | 10 (1.3) | 12 (1.0) | ||
| Total | 791 (100) | 1166 (100) | < 0.001 | |